Education
About Us
Working with TipRanks
Follow Us
Medexus Pharmaceuticals (TSE:MDP)
:MDP
RESEARCH TOOLSreports
MDP Stock Chart & Stats
Day’s Range― - ―
52-Week RangeC$1.71 - C$5.56
Previous CloseN/A
Volume43.25K
Average Volume (3M)39.70K
Market Cap
C$90.65M
Enterprise ValueC$79.07M
Total Cash (Recent Filing)C$23.97M
Total Debt (Recent Filing)$37.18M
Price to Earnings (P/E)21.9
Beta0.70
Next Earnings
Aug 06, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding32,258,354
10 Day Avg. Volume36,132
30 Day Avg. Volume39,705
Financial Highlights & Ratios
PEG Ratio1.02
Price to Book (P/B)-1.92
Price to Sales (P/S)0.00
P/FCF Ratio3.17
Enterprise Value/Market Cap0.87
Enterprise Value/Revenue0.18
Enterprise Value/Gross Profit1.40
Enterprise Value/Ebitda1.09
Forecast
1Y Price Target
C$6.67Price Target Upside131.60% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Medexus Pharmaceuticals Inc News
PremiumCompany Announcements
Medexus Pharmaceuticals’ Earnings Call Highlights GRAFAPEX Success
PremiumCompany Announcements
Medexus Secures Public Reimbursement for Trecondyv® in Quebec
PremiumCompany Announcements
Medexus Reports Strong Initial Uptake of GRAFAPEX™ in U.S. Market
PremiumCompany Announcements
Medexus Returns Gleolan U.S. Rights to NX Development Corp.Bulls Say, Bears Say
Bulls Say
Market GrowthCanadian unit demand for Trecondyv grew 70% and the drug holds a significant market share in pediatric and adult alloHSCT markets in Canada.
Product LaunchGrafapex has shown early success in the U.S., with positive formulary inclusion from commercial payers and healthcare institutions.
Bears Say
Generic CompetitionTotal revenues decreased 4.6% year-over-year, a decline expected due mainly to generic pressure on Rupall.
Profitability IssuesManagement has decided to no longer sell Gleolan in the U.S. as the product was not profitable.
Options Prices
Currently, No data available
---
Ownership Overview
7.36% Insiders
0.45%
Mutual Funds
0.03% Other Institutional Investors
92.14% Public Companies and
Individual Investors
MDP FAQ
What was Medexus Pharmaceuticals’s price range in the past 12 months?
Medexus Pharmaceuticals lowest stock price was C$1.71 and its highest was C$5.56 in the past 12 months.
What is Medexus Pharmaceuticals’s market cap?
Medexus Pharmaceuticals’s market cap is C$90.65M.
When is Medexus Pharmaceuticals’s upcoming earnings report date?
Medexus Pharmaceuticals’s upcoming earnings report date is Aug 06, 2025 which is in 17 days.
How were Medexus Pharmaceuticals’s earnings last quarter?
Medexus Pharmaceuticals released its earnings results on Jun 25, 2025. The company reported -C$0.027 earnings per share for the quarter, beating the consensus estimate of -C$0.087 by C$0.059.
Is Medexus Pharmaceuticals overvalued?
According to Wall Street analysts Medexus Pharmaceuticals’s price is currently Undervalued.
Does Medexus Pharmaceuticals pay dividends?
Medexus Pharmaceuticals does not currently pay dividends.
What is Medexus Pharmaceuticals’s EPS estimate?
Medexus Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Medexus Pharmaceuticals have?
Medexus Pharmaceuticals has 32,258,354 shares outstanding.
What happened to Medexus Pharmaceuticals’s price movement after its last earnings report?
Medexus Pharmaceuticals reported an EPS of -C$0.027 in its last earnings report, beating expectations of -C$0.087. Following the earnings report the stock price went down -5.97%.
Which hedge fund is a major shareholder of Medexus Pharmaceuticals?
Currently, no hedge funds are holding shares in TSE:MDP
Medexus Pharmaceuticals Inc Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
C$6.67 (131.60% Upside)
C$6.67 (131.60% Upside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
27.14%
12-Months-Change
Fundamentals
Return on Equity
5.27%
Trailing 12-Months
Asset Growth
17.35%
Trailing 12-Months
Company Description
Medexus Pharmaceuticals
Medexus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada and the United States. It focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, and allergy. The company's primary products are Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B; and Rupall, a prescription allergy medication. Its products portfolio also includes Treosulfan, a bifunctional alkylating agent for allogeneic hematopoietic stem cell transplantation; Trispan, a triamcinolone hexacetonide injectable suspension; and Gleolan, an optical imaging agent indicates for patients with glioma symptoms. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. is based in Bolton, Canada.
MDP Stock 12 Month Forecast
Average Price Target
C$6.67
▲(131.60%Upside)